**CURRICULUM VITAE**

Heidi J. Wehring, PharmD, BCPP

Assistant Professor, Department of Psychiatry Maryland Psychiatric Research Center University of Maryland School of Medicine

**Contact Information:**

Business Address: University of Maryland School of Medicine

Maryland Psychiatric Research Center

Maple and Locust Streets, Tawes Building 259B Baltimore, MD 21228

Business Phone Number: (410) 402-6842

Mobile Phone Number: (917-282-9128)

Email Address: hwehring@mprc.umaryland.edu

**Education:**

December 1995 BS with High Distinction, Major: Psychology

University of Iowa College of Liberal Arts, Iowa City, Iowa

May 2000 PharmD with High Distinction

University of Iowa College of Pharmacy, Iowa City, Iowa

**Postgraduate Education and Training:**

July 2000-Jun 2001 Psychiatric Pharmacy Practice Residency, University of Maryland School of

Pharmacy (UMSOP)

Mar 2008-Mar 2011 T32 Fellowship in Psychiatry, University of Maryland School of Medicine

(UMSOM), Maryland Psychiatric Research Center (MPRC) T32 Grant number T32MH067533

**Certifications:**

Dec 2003 Board Certified Psychiatric Pharmacist (BCPP) by the Board of

Pharmaceutical Specialties

**Pharmacist Licensure:**

|  |  |  |
| --- | --- | --- |
| Active | Iowa: | Issued 2000 |
| Active | Maryland: | Issued 2000 |
| Active | California: | Issued 2007 |
|  |  |  |

**Employment History:**

**Academic Appointments**

Aug 2002-July 2006 Assistant Clinical Professor, St. John’s University

College of Pharmacy & Allied Health Professions

Clinical Coordinator of Psychiatric Pharmacy

The Zucker Hillside Hospital, Queens, New York

Aug 2006-2008 Assistant Professor/Post-Doctoral Fellow

Touro University-California, College of Pharmacy Vallejo, CA

(split position 50% faculty appointment and 50% post-doctoral fellowship research appointment).

July 2010-2012 Instructor, UMSOM, Dept of Psychiatry/MPRC

Sept 2010-December 2013 Affiliate Faculty, Loyola University Maryland

Department of Psychology, Baltimore, MD

July 2012-present Assistant Professor, University of Maryland School of Medicine

Department of Psychiatry, Maryland Psychiatric Research Center

**Other Appointments:**

July 2001-July 2002 UMSOP, Clinical Pharmacist, Associate Staff

**Professional Society Memberships:**

2002-Present Member, American Association of Colleges of Pharmacy

1999-Present Member, American Society of Health-System Pharmacists

2000-present Member, College of Psychiatric and Neurologic Pharmacists (CPNP)

2001-2005 Member of Communications Committee, CPNP

2003-2005 Member New York Chapter, American College of Clinical Pharmacy

2005-2009 Member of Recertification Committee, CPNP

2009-Present Member, Society for Research on Nicotine and Tobacco

2013-Present Member, Student Committee, CPNP

2015-Present Chair, Student Committee, CPNP

**Honors and Awards:**

1995 Inducted into Phi Beta Kappa Liberal Arts Honor Society

1995 Inducted into Psi Chi Psychology Society

1997 Inducted into Phi Lambda Sigma Pharmacy Leadership Society

1998 Inducted into Rho Chi Pharmacy Society

2000 Facts and Comparisons Award, University of Iowa

2000 Outstanding Psychiatric Pharmacy Student Award, Univ of Iowa

2012 H. McKee Jarboe Award for Mental Health Research, UMSOM

2014 American College of Neuropsychopharmacology, Travel Awardee

**Clinical Activities:**

2001-2002 UMSOP: Performed drug utilization reviews, investigated adverse drug reactions, researched and answered drug information questions, provided staff and patient education, performed dispensing duties, and served as a residency and student preceptor at three State of Maryland Psychiatric Hospitals. Participated in ongoing research, and worked as part of the Clozapine Authorization and Monitoring Program, as well as performing authorization evaluations for patients with paraphilias who were candidates for pharmacological intervention in the State of Maryland system. Worked in conjunction with colleagues in the College of Pharmacy and the Maryland Psychiatric Research Center on a research project involving clozapine and mortality. This was a full-time position.

2002-2006 St. John’s University and The Zucker Hillside Hospital: Served as a full time clinical faculty member at St. John’s University. Teaching responsibilities included lecturing in and/or coordinating several different courses and serving as sole preceptor for pharmacy students on clinical externships at the Zucker Hillside Hospital. Clinical practice responsibilities were fulfilled by serving as Clinical Coordinator of Psychiatric Pharmacy at the Zucker Hillside Hospital. Selected responsibilities included participating as a part of the treatment team on an inpatient unit, acting as a consultant for physicians, residents, and staff throughout the hospital and outpatient clinics, developing and participating in research initiatives, leading weekly patient medication education groups, answering drug information questions, lecturing to Psychiatry Residents on selected topics, and performing various duties as a member of the Pharmacy & Therapeutics Committees of both The Zucker Hillside Hospital and Long Island Jewish Medical Center.

2010-2012 UMSOM: Provision of backup pharmacy services to MPRC

during absences of the regular MPRC pharmacist, provides pharmacy services such as medication preparation, dispensing, and participant consultation. After the dispensing pharmacist left MPRC, interim responsibilities included providing pharmacy services and assisting in the search and hiring processes for new pharmacy staff. This entailed between 2 and 10 hours weekly.

2010-present UMSOM: Provision of pharmacological and pharmaceutical expertise to

MPRC faculty and clinical staff. This entails approximately 2-5 hours weekly.

2011-present UMSOM: Peer Review Program for Mental Health Medication in Children and Adolescents, Co-Principal Investigator. Provision of supervision, planning, and clinical expert pharmacist review for a joint Medicaid project involving the University of Maryland Schools of Medicine. This program involves reviewing authorization requests for children under age 18 who are prescribed antipsychotic medications under Maryland Medicaid funding. Activities include both participating in developing the program as well as providing ongoing clinical pharmacist review for applications for authorization.

2016-present UMSOM: Team member establishing telepsychiatry consultation services for providers and patients on the Eastern Shore of MD.

**Administrative Service:**

**Institutional Service**

2002-2006 The Zucker Hillside Hospital, Pharmacy &Therapeutics Committee

2002-2006 L.I. N.Y. Jewish Medical Ctr Pharmacy &Therapeutics Committee

2005-2006 St. John’s University College of Pharmacy and Allied Health: Chair, Ad Hoc Committee for Honors Program

2006-2008 Touro University-California: Academic Standards Committee

2009-2012 UMSOM: Organize monthly fellow & junior faculty meetings with

MPRC Director, Dr. William T. Carpenter

2010-present UMSOM: Support pharmacy services at MPRC & search committee

2010-present UMSOM: As needed teaching for residents, fellows, and students.

2014-present Department of Psychiatry Research Day ,UMSOM Planning Committee

2016-present Alternate Member, UMSOM Council

**Local and National Service:**

**Local Service**

2005 New York Chapter, American College of Clinical Pharmacy

Member of Fall Programming Committee

**National Service**

2001-2005 College of Psychiatric and Neurologic Pharmacists (CPNP),Communications Committee

2005-2009 CPNP BCPP Recertification Committee

2011, 2013 Speaker for Recertification Review Course for BCPP

2011-present CPNP, Abstract Reviewer for Annual Meeting

2012-present Reviewer for Schizophrenia Bulletin, Journal of Disabilities

2013-2014 SRNT, Abstract Reviewer for Annual Meeting

2013-present CPNP Student Committee Member

2014 Volunteer, National Alliance on Mental Illness Annual Meeting

2014-2015 CPNP Student Committee Vice-Chair

2015-present CPNP Student Committee Chair

2015-present CPNP Substance Abuse Task Force Member

**Teaching Service:**

Aug 2000-Dec 2000 UMSOP, Led discussions and laboratory sessions for pharmacy students.

Aug 2000-May 2001 UMSOP, Participated in course “Educational Theory and Practice”, enhanced course design & implementation, including effective teaching methods. Lectured on Attention Deficit/Hyperactivity Disorder for the Psychiatry module of the Therapeutics course.

July 2002-July 2006 St. John’s University, Assistant Clinical Professor

Teaching duties included lecturing in several team-taught courses, including Drugs and Diseases, Drug Information, Case Studies, and Advanced Therapeutics, coordinating and teaching a Psychotherapeutics elective for graduate students and serving as a preceptor for Pharmacy students at the Zucker Hillside Hospital.

July 2002-July 2006 Clinical Coordinator, Psychiatric Pharmacy, Zucker Hillside Hospital In addition to precepting PharmD students on clerkships, teaching experiences included formal lectures to the Psychiatry Residents, lecturing to nurses, pharmacists, and health care professionals, leading patient medication education groups on inpatient units.

Aug 2006-Present Touro University-California, Assistant Professor

Teaching duties include coordinating the second-year therapeutics curriculum, as well as teaching in the first and second-year curriculum, serving as faculty advisor to students, and collaborating with other faculty in the PharmD program.

Sept 2010-2013 Loyola University Maryland, Affiliate Faculty

Taught a semester-long course in Psychopharmacology during Fall semester for third year Doctor of Psychology (PsyD) students at Loyola University Maryland.

July 2010-2012 UMSOM, Instructor

Provided as-needed lectures for residents, particularly in the

Pyschopharmacology seminar for fourth year residents (one lecture 2010, two lectures in 2011). Provided as-needed mentoring and precepting for pharmacy students, medical residents, and fellows.

July 2012-present UMSOM, Assistant Professor

Provides as-needed lectures for residents, particularly in the

Psychopharmacology seminar for fourth year residents, as well as child and adolescent psychiatry fellows. Provided as-needed mentoring and precepting for pharmacy students, medical residents, and fellows. Provides yearly journal clubs for child and adolescent fellows, as well as second-year psychiatry residents, and T32 fellows. Mentored PharmD students in a year-long experiential course on Healthy Aging. Lecture yearly on tobacco craving to the second year medical students in the combined accelerated program in psychiatry. Yearly lecture to Psychology Interns at Spring Grove Hospital Center.

2015-present Member, Department of Psychiatry Planning Committee

2015-present Department of Psychiatry Poster Judge

2016-present Alternate, School of Medicine Council

**Grant and Contract Support:**

**Current Grant and Contract Support**

4/2013 – 3/2018 Heidi Wehring, PI, 85% funded effort

NIDA K23 DA034034

“Tobacco Craving in Smokers with Schizophrenia”. Total costs: $216,198.05

8/2016-4/2020 Co-Investigator, (15% funded effort, Gloria Reeves, MD, PI)

NIMH R01MH110945

“A Community-based ,family Navigator intervention to improve cardiometabolic health of Medicaid-insured youth identified through an antipsychotic medication preauthorization program”

Total Direct Costs for year 1: $487,524

10/2011 – continuous: Contract Co-PI (10% funded effort) Ray Love, PI

“Peer Review for Mental Health Drugs Program”

This is a contract between Maryland Medicaid and the University of Maryland Schools of Pharmacy and Medicine

Total Direct Costs for year 1: $390,875

**Completed Grants**

1/2013 – 5/2016 Co-Investigator, 5% funded effort

Gloria Reeves, MD, PI

PCORI RFA- Improving Healthcare Systems

“The Family VOICE (Value of Information, Community Support, and Experience) Study”

Total Direct Costs: $398,604

04/2011 – 04/2013 Co-Investigator, 5%\* (note, my funding on this project has been eliminated in order to comply with NIH restrictions on K awardees)

Deanna Kelly, PI

“Adjunctive Minocycline in Clozapine Treated Patients for

Psychosis and Cognition” NIH/NIMH R21

Direct Costs for year 1: $202,500

9/2010 – 8/2015 Collaborator, 5%\* (note, my funding on this project has been eliminated in order to comply with NIH restrictions on K awardees)

Jia Bei Wang, MD, PhD, PI

“Development of l-THP as New Medication for Drug Addiction” NIDA (1DP1DA031401-01)

Total Direct Costs: $2,500,000

9/2008 – 5/2013 Research Staff (15%)\* (note, my funding on this project has been eliminated in order to comply with NIH restrictions on K

awardees)

Robert Buchanan, PI

“MPRC Centers for Intervention Development and Applied

Research (CIDAR)”

NIMH (1P50 MH082999) Costs: $1,999,879

7/2012 – 6/2013 Co-Investigator, 25% funded effort\* (note, my funding on this project has been eliminated in order to comply with NIH restrictions on K awardees)

“State of Maryland Medicaid Antipsychotic Utilization Review” Raymond Love, PI

This is a contract between Maryland Medicaid and the University of Maryland Schools of Pharmacy and Medicine.

Total Direct Costs for year 1: $699,890

7/2005-6/2012 Co-Investigator, 34% Deanna Kelly, PI

N01-DA-5-9909

NIDA Residential Research Support Services

Costs $13,074,663

3/2008-3/2010 T32 Fellow

William T. Carpenter, PI NIH/NIMH T32MH0

T32 Fellowship

**Publications:**

**Journal Articles, Reviews, and Letters**

Rubin LH, **Wehring HJ**, Demyanovich H, Carter CS, Pournajafi-Nazarloo H, Feldman SM, Earl AK, August S, Gold JM, Kelly DL. Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia. Schizophrenia Research 2017, in press.

**Wehring HJ**\*, Elsobky T\*, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon E, Kelly DL. Adjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levels. Psychiatric Quarterly, in press 2017.

Reeves G, **Wehring HJ**, Edwards S, dosReis S. Partnership with consumers to improve research dissemination. Medical Research Archives [Epub ahead of print], 2017.

**Wehring HJ,** Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, Weiner E, Kelly DL. Antipsychotic treatment and tobacco craving in people with schizophrenia. J Dual Diagn 2017 Feb; [Epub ahead of print]. PMID: 28166471.

William J. Kowalczyk, **Wehring HJ**, George Burton, Heather Raley, Stephanie Feldman, Stephen J Heishman, Deanna L. Kelly. Predictors of the Perception of Smoking Health Risks in Smokers with or without Schizophrenia. J Dual Diagn 2016 Nov; [Epub ahead of print]. PMID: 27858591

Hassan HE, Kelly D, Honick M, Shukla S, Ibrahim A, Gorelick DA, Glassman M, McMahon RP,**Wehring HJ**, Kearns AM, Feldman S, Yu M, Bauer K, Wang JB.

Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Pharmacol. 2016 Jul 1. doi: 10.1002/jcph.789. [Epub ahead of print]

Lee MR, **Wehring HJ**, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL. Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophr Res. 2016 Apr;172(1-3):165-8. doi: 10.1016/j.schres.2016.02.014. Epub 2016 Feb 12.

**Wehring HJ\***, Lee ML\*, McMahon RP, Linthicum J, Buchanan RP, Strauss GP, Kelly DL. Oyxtocin and social cognition in schizophrenia: a randomized, double blind clinical trial. Under review, 2016.

**Wehring HJ,** Heishman SJ, McMahon RP, Turner HE, Taylor R, Fischer B, Rowland LR, Kelly DL. Assessment of cannabis craving in smokers with schizophrenia. In preparation, 2015.

Reeves G, **Wehring HJ**, Connors K, Bussell K, Schiffman J, Medoff D, Tsuji T, Walker J, Brown A, Strobeck D, Clough T, Rush C, Riddle M, Love RC, Zachik A, Hoagwood K, Olin S, Stephan S, Pruitt D, Okuzawa N, Edwards S, Baquet C, dosReis S. The Family VOICE (Value of Information, Community Support, and Experience) Study: rationale, design, and methods of a “family-centered” research study. J Nerv Ment Dis. 2015 Dec;203(12):896-900.

Koola MM, Sullivan KM, Earl AK, Feldman SM, Richardson C, Vyas GR, **Wehring HJ**, Kelly DL. Undiagnosed Lyme disease in adults with schizophrenia. Schizophr Res. 2015 Oct;168(1-2):579-80. doi: 10.1016/j.schres.2015.06.029.

Miller J, **Wehring HJ**, McMahon RP, DiPaula BA, Love RC, Morris AA, Raley H, Feldman S, Kelly DL. Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. Human Psychopharmacology 2015. Doi: 10.1002/hup.2482 [Epub ahead of print].

Fischer BA, McMahon RP, Kelly DL, **Wehring HJ**, Meyer WA, Feldman S, Carpenter WT, Gorelick DA. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophr Res 2015;161(2-3):471-7.

Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, **Wehring HJ**, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol. 2015 Aug;35(4):374-81.

Kelly DL, Ben-Yoav H, Payne GF, Winkler TE, Chocron SE, Kim E, Stock V, Vyas G, Love RC,**Wehring HJ**, Sullivan KM, Feldman S, Liu F, McMahon RP, Ghodssi R.

Blood Draw Barriers for Treatment with Clozapine and Development of Point-of-Care Monitoring Device. Clin Schizophr Relat Psychoses. 2015 Jul 28. [Epub ahead of print]

Koola MM, Gorelick DA, McMahon RP, Liu F, Huestis MA, Linthicum J, Feldman SM, Warren KR,**Wehring HJ**, Kelly DL. Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. Schizophr Res 2014;152(1):315-6.

**Wehring HJ**, Perez G, Dixon L, Kelly DL. Women and Addiction: Compounding the picture with mental illness. Current Women’s Health Reviews, 2013.

Kelly DL, **Wehring HJ**, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC. [Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).](http://www.ncbi.nlm.nih.gov/pubmed/23968123) BMC Psychiatry. 2013 Aug 22;13:214.

Lee MR, **Wehring HJ**, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013 Apr;145(1-3):110-5.

Love RC, **Wehring HJ**, Coulter JS. Psychotropic Medication Use in Foster Children: An Opportunity for Psychiatric Pharmacists. Ment Health Clin. 2013;2(11):92.

Keller, WR, Kum LM, **Wehring HJ**, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol

2013;27(4):337-42.

**Wehring HJ**, Liu F, McMahon RP, Mackowick KM, Love RC, Dixon L, Kelly DL. Clinical Characteristics of Heavy and Light Smokers with Schizophrenia. Schizophrenia Research; 138(2-3):285-9. PMID: 22578720

Koola MM, McMahon RP, **Wehring HJ**, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res 2012;46(8):987-93.

Mackowick KM, Heishman SJ, **Wehring HJ**, Liu F, McMahon R, Kelly DL, Illicit drug use in heavy smokers with and without schizophrenia, Schizophr. Res. (2012), doi:

10.1016/j.schres.2012.04.012

Kelly DL, **Wehring HJ**, Vyas G. Current Status of Clozapine in the United States. Shanghai Archives of Psychiatry 2012;24(2):110-3.

Koola MM, **Wehring HJ,** Kelly DL. The potential of long acting injections in people with schizophrenia and a comorbid substance use disorder. Journal of Dual Diagnosis

2012;8(1):50-61.

**Wehring HJ**, Carpenter WT. Violence and schizophrenia. Schizophr Bull

2011;37(5):877-878.

Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, **Wehring HJ**. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 2011;133(1-3):257-8.

**Wehring HJ**, Thedford S, Koola MJ, Kelly DL. Olanzapine long acting injection in Schizophrenia: Adherence and Patient and Health Care Provider Perspectives. Journal of Central Nervous System Disease 2011;3:107-23.

Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, **Wehring HJ**, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011 Feb;31(1):86-91.

Kelly DL**,** Vyas G, Thedford S, **Wehring HJ,** Koola M, Richardson C. A Blood Based Diagnostic Aid Improves Insight in a Patient with Schizophrenia: A Case Report. Submitted, 2011.

Kelly DL, McMahon RP, **Wehring H,** Liu F, Mackowick K, Boggs DL, Warren K, Feldman S, Shim J, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schiz Bulletin 2011;37:832-8 PMID 20019128

Kelly DL, Gallagher H, Lo S, Wright K, Moolchan E, Feldman S, Liu F, McMahon RP, Richardson CM, Jaszyna-Gasior M, **Wehring HJ**, Boggs D, Heishman S. Perception of Smoking Risks and Motivation to Quit among Non-Treatment Seeking Smokers With and Without Schizophrenia. Schizophrenia Bull 2010; Epub ahead of print. PMID: PMC Journal – In Process

**Wehring HJ**, Liu F, McMahon RL, Spieker EA, Boggs DL, Dickinson D, Shim JC, Fowler D, Kelly DL. The Relationship of Brain Weight to Body Mass Index (BMI) Upon Autopsy in Patients With Severe Mental Illness. Schizophr Res 2010;123(1):86-87. PMID:20800997.

Kelly DL, McMahon RP, Liu F, Love RC, **Wehring HJ**, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010;71(3):304-11.

Lo S, Heishman SJ, Raley H, Wright K, **Wehring HJ**, Moolchan ET, Feldman S, Liu F, McMahon RP, Richardson CM, Kelly DL. Tobacco craving in smokers with and without schizophrenia. Schizophr Res 2010; Epub ahead of print. PMID: 20637571

Barnett MJ, Frank J**, Wehring H**, Newland B, VonMuenster S, Kumbera P, Halterman T, Perry PJ. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm 2009;15(1):18-

31.

Kelly DL, **Wehring HJ**, Linthicum J, Feldman S, McMahon RP, Love RC, Wagner T, Shim JC, Fowler DR. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophr Res. 2009;107(2-3):134-8.

Mészáros K, Barnett MJ, McDonald K, **Wehring H,** Evans DJ, Sasaki-Hill D, Goldsmith PC, Knapp KK. Progress examination for assessing students' readiness for advanced pharmacy practice experiences. Am J Pharm Educ. 2009 Oct 1;73(6):109.

Barnett M, VonMuenster S, **Wehring H,** Popish S, McDonald K, Walker VM, Perry P. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics. Ann Clin Psychiatry 2010;22(1):9-18.

Barnett M, **Wehring H,** Perry P. Comparison of Risk of Cerebrovascular Events in an Elderly VA Population with Dementia Between Antipsychotic and Non-Antipsychotic Users. J Clin Psychopharmacol 2007;27(6):595-601.

El-Chaar GM, Maisch NM, Augusto LM, **Wehring HJ**. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Annals of Pharmacotherapy 2006;40(6):1086-95.

Kelly DL, **Wehring H**, McMahon RP, Love RC, Yu Y, Conley RR. Mortality in schizophrenia patients treated with second-generation antipsychotics. Schiz Res 2003 (suppl 1):41.

**Wehring HJ**, Kelly DL, Love RC, and Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment (Letter to the Editor). American Journal of Psychiatry 2003;160:2241-2242.

Ellingrod VL, Miller D, Schultz SK, **Wehring H,** and Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric Genetics. 2002; 12:55-8.

**Wehring HJ**, Alexander B, and Perry P. Two Cases of Diabetes Mellitus Associated with Clozapine Therapy. Pharmacotherapy 2000, Vol 20(7): 844-47.

**Book Chapters:**

Millman ZB, **Wehring HJ,** Khan AM, Edwards S, Hoover SA, Schiffman J. School Psychopharmacology: Effective Medications for Treating Psychosis. In Translating Research Into Practice. In press, 2017.

Reeves GM, **Wehring HJ**, Riddle MA. Pharmacotherapy of Disruptive and Impulse Control Disorders. In The Wiley Handbook of Disruptive and Impulse-Control Disorders**,** J.E. Lochman & W. Matthys, Eds, in press 2017.

**Wehring HJ,** Kelly DL. Schizophrenia. In Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, eds. In Pharmacotherapy Principles and Practice, 4rd Edition. New York: McGraw Hill Medical, 2015.

**Wehring HJ.** Schizophrenia and Related Psychotic Disorders Pharmacotherapy. In

BCPP Examination and Recertification Review Course, 2014-2015.

**Wehring HJ,** Kelly DL. Schizophrenia. In Katz M, Matthias KR, Chisholm-Burns MA, eds. In Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach, Third Edition. New York: McGraw Hill Medical, 2013.

**Wehring HJ.** Schizophrenia and Related Psychotic Disorders Pharmacotherapy. In

BCPP Examination and Recertification Review Course, 2012-2013.

Kelly DL, Weiner E, **Wehring HJ**. Schizophrenia. In Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, eds. In Pharmacotherapy Principles and Practice, 3rd Edition. New York: McGraw Hill Medical, 2012.

**Wehring HJ,** Kelly DL. Schizophrenia. In Katz M, Matthias KR, Chisholm-Burns MA, eds. In Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach. New York: McGraw Hill Medical, 2011.

Kelly DL, Weiner E, **Wehring HJ**. Schizophrenia. In Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, eds. In Pharmacotherapy Principles and Practice, 2nd Edition. New York: McGraw Hill Medical, 2010.

**Wehring HJ**, Kelly DL. Sexual dysfunction and schizophrenia. In Meyer JM, Nasrallah HA, eds. Medical Illness and Schizophrenia, 2nd Edition. Arlington, VA: American Psychiatric Publishing, Inc. 2009.

Perry P, **Wehring H**, Alexander B, Liskow B. Clinical psychopharmacology and other somatic therapies. In Fatemi SH, Clayton P, eds. The Medical Basis of Psychiatry. Totowa, NJ: Humana Press 2007.

**Invited Speeches:**

**International Presentations:**

"A Pilot Study of the Effects of Adjunctive Intranasal Oxytocin to Improve Social Cognition and Functioning in Schizophrenia”, April, 2012. Presented at the Schizophrenia International Research Society (SIRS) Biennial Meeting, Florence, Italy.

**National Presentations:**

“Overview: AACAP Guidelines on Pediatric Atypical Antipsychotic Treatment”, May 2016. Co-presented with Gloria Reeves, MD, and Raymond Love, PharmD, for the CMS ADC Affinity Group Meeting, Webinar.

“Medication and Treatment Challenges for the Young Adult”, September 2014. Co-presented with Karen Moeller Thirion, PharmD, BCPP, for the National Alliance on Mental Illness (NAMI) National Convention, Washington, DC.

“Negative Symptoms in Schizophrenia: A Place for Oxytocin?”, April 2014. Presented to the College of Psychiatric and Neurologic Pharmacists Annual Meeting, Phoenix, AZ.

“Schizophrenia and the Psychotic Disorders: Pharmacological Treatments”, September 2013. Presented as an audio recording for the 2014-2015 BCPP Recertification and Review Course.

“Pharmacotherapy of Schizophrenia”, November 2011. Presented as an audio recording for the 2012-2013 BCPP Recertification and Review Course.

**Local Presentations:**

“Psychotropic medications: a symposium for psychologists”, June, 2017. Presented to Maryland Department of Health psychologists, Catonsville, MD.

“Antipsychotics: Review and Update”, November 2016. Presented to Psychology Interns, Spring Grove Hospital Center, Catonsville, Maryland.

“Minocycline and tobacco craving in smokers with schizophrenia”, November 2016. Presented at the 2016 MPRC Neuroscience Day Symposium, Baltimore, MD.

“Perspectives in Mental Health Pharmacy”, September 2016. Participated in a panel discussion for pharmacy students at UMB, Baltimore, MD.

“A Review of Psychotropics for Psychologists”, October 2015. Presented to psychology interns at Spring Grove Hospital Center, Catonsville, MD.

“Medication Management”, September 2015. Co-presented with Kay Connors, MSW, and Gloria Reeves, MD, for the Resource Parent Training Child Welfare Academy, Baltimore, MD.

“Medications for mental health”, August 2015. Co-presented with Gloria Reeves, MD, to Baltimore County School Nurses, Towson, MD.

“Craving research in schizophrenia”, March 2015. Presented to the CAPP Medical Students, Baltimore, MD.

“Schizophrenia, smoking and craving”, November 2014. Presented to the Student CPNP Chapter of UMB School of Pharmacy, Baltimore, MD.

“Psychiatric pharmacy practice”, October 2014. Participated at a Round Table for Dr. Bethany DiPaula’s Mental Health Elective, UMB School of Pharmacy, Baltimore, MD.

“Depression treatment: efficacy and effectiveness”, September 2014. Presented to Dr. Leo Tonelli’s lab, UMB SOM, Baltimore, MD

“Pharmacological treatment of schizophrenia”, March 2014. Presented to undergraduate students in the Schizophrenia elective, Department of Psychology, University of Maryland Baltimore County-Shady Grove, MD.

“Ziprasidone in Bipolar Disorder”, February 2014. Presented as a journal club to the PGY-2 Psychiatry Residents, Baltimore, MD.

“Lamotrigine in Obsessive Compulsive Disorder”, June 2013. Presented as a journal club to the PGY-2 Psychiatry Residents, Baltimore, MD.

“Tobacco Craving in Schizophrenia”, December 2013. Presented as a journal club to the Child and Adolescent fellows, University of Maryland SOM, Baltimore, MD.

“Ziprasidone for Children and Adolescents”, December 2013. Presented as a journal club to the T32 NIMH MPRC fellows, Baltimore, MD.

“Psychopharmacology: Review and general update”, March 2013. Presented as a

Continuing Education seminar to psychology staff at Spring Grove Hospital Center, Catonsville, MD.

“Prolactin-related side effects of antipsychotics”, February 2013. Journal club presented to Child and Adolescent fellows, University of Maryland School of Medicine, Baltimore, MD.

“Weight gain among psychotropic medications”, December 2012. Presented to psychiatry residents as part of Psychopharmacology curriculum, University of Maryland School of Medicine, Baltimore, MD.

“Gender-based side effects of antipsychotic medications”, September 2012. Presented to members of Howard County National Alliance on Mental Illness, Columbia, MD.

“How do I build an all-star research team?”, May 2012. Co-presented with Dr. Kathryn Walker as Continuing Education programming, University of Maryland School of Pharmacy, Baltimore, MD.

“Antipsychotic efficacy in early onset schizophrenia”, May 2012. Presented as a journal club to the third year Psychiatry Residents, University of Maryland School of Medicine, Baltimore, MD.

“The Peer to Peer program: A New Medicaid pre-authorization program for antipsychotic treatment of young children”, March 2012. Co-presented with Gloria Reeves, MD, and Raymond C. Love, PharmD, at the Maryland Mental Hygiene Administration’s (MHA) Eighth Annual Child and Adolescent Mental Health Conference, titled “Integrating Clinical Interventions Within A Behavioral Health Approach”, Baltimore, Maryland.

“Case Studies in Psychopharmacology”, November 2011. Co-presented with Dr. Deanna Kelly to PGY-4 Psychiatry residents during Psychopharmacology seminar, University of Maryland School of Medicine, Baltimore, MD.

“Metabolic complications of antipsychotic medications”, September 2011. Presented to PGY-4 Psychiatry residents during Psychopharmacology seminar, University of Maryland School of Medicine, Baltimore, MD.

“Psychotropic medications and weight gain liability”, October 2010. Presented to PGY-4

Psychiatry residents during Psychopharmacology seminar, University of Maryland School of Medicine, Baltimore, MD.

“Assessment of Craving in Smokers with Schizophrenia using Virtual Reality”, September 2010. Presented at the 2010 Neuroscience Day to faculty and staff from the Maryland Psychiatric Research Center, National Institute on Drug Abuse Intramural Research Program, and University of Maryland Department of Psychiatry, Baltimore, MD.

“Treatment of Alzheimer’s Disease: Focus on Non-Cognitive Symptoms”, February 2008. Presented to Psychiatry staff at Napa State Hospital Center, Napa, CA.

“Treatment of Alzheimer’s Disease: Focus on Cognitive Symptoms”, December 2007. Presented to Psychiatry staff at Napa State Hospital Center, Napa, CA.

“Monitoring Antipsychotic Medications”, November 2007. Presented to Psychiatry staff at Napa State Hospital Center, Napa, CA.

Barnett, Mitchell J., **Wehring, Heidi J**., and Perry, Paul J. “Trends in Medication Therapy Management: The First Decade”. Findings Presented at Get Outcomes Pharmaceuticals. Des Moines, IA, April 2007.

“Treatment Adherence in Severe Mental Illness”, March 2007. Presented to the

Psychiatry staff at Napa State Hospital Center, Napa, CA.

“Evidence-Based Treatment of Insomnia”, January 2007. Presented to the Psychiatry staff at Napa State Hospital Center, Napa, CA.

“Eating Disorders: Treatment Options”, April 2006. Presented to Pharmacy staff at The

Zucker Hillside Hospital, Glen Oaks, NY.

“Strategies to Impact Treatment Adherence in Schizophrenia”, March 2006. Presented to Psychiatry Residents as part of a teaching series, The Zucker Hillside Hospital, Glen Oaks, NY.

“Tardive Dyskinesia”, March 2006. Presented to Pharmacy staff at The Zucker Hillside

Hospital, Glen Oaks, NY.

“Neuroleptic Malignant Syndrome: Detection and Management”, February 2006. Presented to Psychiatry Residents during the Schizophrenia module of PGY-1 curriculum, The Zucker Hillside Hospital, Glen Oaks, NY.

“Movement Disorders and Antipsychotics”, February 2006. Presented to Psychiatry Residents during the Schizophrenia module of PGY-1 curriculum, The Zucker Hillside Hospital, Glen Oaks, NY.

“SSRIs and Youth”, May 2005. Presented as a Continuing Education program at the

2005 Pediatric Symposium, St. John’s University, Jamaica, NY.

“Psychotropic Medications: An Overview”, March 2005. Presented to nurses at the North

Shore-Long Island Jewish Nursing Core Curriculum Seminar, New Hyde Park, NY.

“Mysteries of Medication” November 2003. Presented to New York City Mood Disorders Support Group, New York City, NY.

“Depression in the Oncology Patient: Treatment Considerations”, May 2003. Presented as a Continuing Education program at the 2003 Oncology Update, St. John’s University, Jamaica, NY.

“Pain Control in the Psychiatric Patient”, September 2001. Presented as Grand Rounds to staff at Spring Grove Hospital Center, Catonsville, MD.

“Bupropion for the treatment of ADHD in Adults”, April 2001. Presented to pharmacists and residents as Continuing Education presentation, University of Maryland, Baltimore, MD.

“The Mental Status Assessment”, February 2001. Presented to Advanced Patient

Assessment Class, University of Maryland School of Pharmacy, Baltimore, MD.

“Diabetes and Schizophrenia”, February 2001. Presented to nursing students and community residence sponsors, Department of Veteran’s Affairs, Perry Point, MD.

“Clozapine, Weight Gain, Diabetes, and Lipid Abnormalities: Is There a Connection?” September 2000. Presented to pharmacists and residents as Continuing Education presentation, University of Maryland, Baltimore, MD.